Predicting the outcomes of subjects with severe community-acquired pneumonia using monocyte human leukocyte antigen-DR

Respiratory Care

Volumn 60, Issue 11, 2015, Pages 1635-1642

  Zhuang, Yugang ^a   Li, Wenjie ^a   Wang, Huiqi ^a   Peng, Hu ^a   Chen, Yanqing ^a   Zhang, Xiangyu ^a   Chen, Yuanzhuo ^a   Gao, Chengjin ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

MHLA DR; Prognosis; Severe pneumonia; Single time point

Indexed keywords

LEUKOCYTE ANTIGEN; MONOCYTE HUMAN LEUKOCYTE ANTIGEN DR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HLA DR ANTIGEN;

ANTIBIOTIC THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD ANALYSIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; FLOW CYTOMETRY; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; MONOCYTE; RETROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ADULT; AGED; AREA UNDER THE CURVE; BLOOD; COMMUNITY ACQUIRED INFECTION; FEMALE; IMMUNOLOGY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PNEUMONIA; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APACHE; AREA UNDER CURVE; BIOMARKERS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HLA-DR ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MONOCYTES; PNEUMONIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84944718543     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.03953     Document Type: Article

References (32)

1. Ewig S, Woodhead M, Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011; 37(2):214-223.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of com- munity-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-S72.
3. Gouel-Chéron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G, et al. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the devel- opment of sepsis after major trauma. PLoS One 2012;7(3):e33095.
4. Genel F, Atlihan F, Ozsu E, Ozbek E. Monocyte HLA-DR expression as predictor of poor outcome in neonates with late onset neo- natal sepsis. J Infect 2010;60(3):224-228.
5. Lin ZQ, Guo J, Xia Q, Yang XN, Huang W, Huang ZW, Xue P. Human leukocyte antigen-DR expression on peripheral monocytes may be an early marker for secondary infection in severe acute pancreatitis. Hepatogastroenterology 2013;60(128):1896-1902.
6. Wu JF, Ma J, Chen J, Ou-Yang B, Chen MY, Li LF, et al. Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis. Crit Care 2011;15(5):R220.
7. Berry PA, Antoniades CG, Carey I, McPhail MJ, Hussain MJ, Davies ET, et al. Severity of the compensatory anti-inflammatory re- sponse determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis. Intensive Care Med 2011;37(3):453-460.
8. Lukaszewicz AC, Grienay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B, Payen D. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection predic- tion. Crit Care Med 2009;37(10):2746-2752.
9. Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, Fuerst W, et al. Lipopolysaccharide-induced tumor necrosis factor production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 2006;25(2):129-134.
10. Cazalis, Friggeri A, Cavé L, Demaret J, Barbalat V, Cerrato E, et al. Decreased HLA-DR antigen associated invariant chain(CD74) mRNA expression predicts mortality after septic shock. Crit Care 2013; 17(6):R287.
11. Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo YJ. Increased CD14 () HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemother- apy in non-small cell lung cancer patients. Cancer Immunol Immunother 2013;62(9):1439-1451.
12. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med 2008;358(7):716-727.
13. Chalk K, Meisel C, Spies C, Volk T, Thuenemann K, Linneweber J, et al. Dysfunction of alveolar macrophages after cardiac surgery and postoperative pneumonia?: an observational study. Crit Care 2013; 17(6):R285.
14. Simon PM, Delude RL, Lee M, Kong L, Guzik LJ, Huang DT, et al. Duration and magnitude of hypotension and monocyte deactivation in patients with community-acquired pneumonia. Shock 2011;36(6): 553-559.
15. Polk HC, Naziri W, McCurry TM. Immunologic responses to pneumonia. Am J Surg 2000;179(2):41-44.
16. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-adquired, ventilaror-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416.
17. Guan X, Silk BJ, Li W, Fleischauer AT, Xing X, Jiang X, et al. Pneumonia incidence and mortality in Mainland China: systematic review of Chinese and English literature, 1985-2008. PLoS One 2010;5(7):e11721.
18. Renaud B, Santin A, Coma E, Camus N, Van Pelt D, Hayon J, et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-ac- quired pneumonia. Crit Care Med 2009;37(11):2867-2874.
19. Que YA, Lazar H, Wolff M, François B, Laterre PF, Mercier E, et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 2014;33(10):1861-1867.
20. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, random- ized, placebocontrolled multicenter trial. Am J Respir Crit Care Med 2009;180(7):640-648.
21. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008;14(1):64-78.
22. Volk HD, Reinke P, Krausch D. Monocyte deactivation: rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996; 22(Suppl 4):S474-S481.
23. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13(12):862-874.
24. Cabrera-Perez J, Condotta SA, Badovinac VP, Griffith TS. Impact of sepsis on CD4 T cell immunity. J Leukoc Biol 2014;96(5):767-777.
25. Schefold JC, von Haehling S, Corsepius M, Pohle C, Kruschke P, Zuckermann H, et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock 2007;28(4):418-425.
26. Payen D, Faivre V, Lukaszewicz AC, Villa F, Goldberg P. Expression of monocyte human leukocyte antigen-DR in relation with sep- sis severity and plasma mediators. Minerva Anestesiol 2009;75(9): 484-493.
27. Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard AL, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006;32(8): 1175-1183.
28. Pedicino D, Liuzzo G, Trotta F, Giglio AF, Giubilato S, Martini F, et al. Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J Diabetes Res 2013; 2013:184258.
29. Onat A, Donmez I, Karadeniz Y, Cakır H, Kaya A. Type-2 diabetes and coronary heart disease: common physiopathology, viewed from autoimmunity. Expert Rev Cardiovasc Ther 2014;12(6):667-679.
30. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hyper- tension. Circ Res 2014;115(1):165-175.
31. Iliakis D, Kressig RW. The relationship between malnutrition and immune. Ther Umsch 2014;71(1):55-61.
32. Perry SE, Mostafa SM, Wenstone R, Shenkin A, McLaughlin PJ. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?. Intensive Care Med 2003;29(8):1245-1252.